Proteomic profiling reveals dysregulation of cholesterol transport and immune pathways in myeloproliferative neoplasms, indicating metabolic-immune interactions.
Key Points
Cholesterol transport deficiency correlates with increased complement activation in myeloproliferative neoplasms.
Mass spectrometry analysis identified significant alterations in immune and metabolic pathways related to myeloproliferative neoplasms.
Dysregulated immune proteins showed links to inflammation and thrombosis, including key factors identified through proteomics.
These findings support further investigation into the metabolic-immune axis as a target for therapeutic strategies in myeloproliferative neoplasms.